One of the earliest seminal trials demonstrating the abscopal effect involved patients with multiple tumor types receiving granulocyte-macrophage colony-stimulating factor (GM-CSF; 125 mg/m), which is known to be an immunoadjuvant, especially in the setting of RT, that facilitates AR.8 Investigators administered GM-CSF subcutaneously along with radiation and their choice of chemotherapy, noting an AR rate of 27%. The gene discussed is CSF2; the disease is neoplasm.